http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012153978-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 |
| filingDate | 2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012153978-A |
| titleOfInvention | BINDING KIT APTAMERS AND MEANS AGAINST C5, SUITABLE FOR TREATMENT OF EYE VIOLATIONS |
| abstract | 1. A method of treating, stabilizing and / or preventing ocular disorders, the method comprising administering a therapeutically effective amount of an anti-C5 agent in combination with an anti-PDGF agent to a subject in need thereof, the anti-C5 agent being a pegylated or non-pegylated aptamer that binds to C5 complement. 2. The method of claim 1, wherein the pegylated or non-pegylated aptamer has a sequence selected from: SEQ ID NO: 1 through 69, 75, 76, 81, 91, 95, and 96.3. The method according to claim 1, where the pegylated or non-pegylated aptamer has the sequence of SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 67.4. The method according to claim 1, where the anti-C5 agent is a pegylated aptamer having the structure indicated below or its salt: where it indicates fC and fU = 2 '- fluorine nucleotides on the linkerg, and mG and mA = 2' - OMe nucleotides and all other nucleotides are 2'-OH, and 3T indicates inverted deoxythymidine. 5. The method of claim 4, wherein the linker is an alkyl linker. The method according to claim 5, where the alkyl linker contains from 2 to 18 consecutively located CH groups. The method of claim 1, wherein the anti-C5 agent is a pegylated aptamer having the structure shown below: where fC and fU = 2 ′ are fluoronucleotides, and mG and mA = 2 ′ are OMe nucleotides and all other nucleotides are 2'-OH , and where 3T indicates inverted deoxythymidine. 8. A method according to any one of the preceding claims, wherein the ocular disorder is macular degeneration or diabetic retinopathy. The method of claim 8, wherein macular degeneration is age-related macular degeneration (AMD). The method according to claim 9, where age-related macular degeneration (AMD) is |
| priorityDate | 2006-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.